

Pembrolizumab PK Fact Sheet

Reviewed July 2022

Page 1 of 2

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

Details

<i>Generic Name</i>	Pembrolizumab
<i>Trade Name</i>	Keytruda®
<i>Class</i>	Antineoplastic agents, monoclonal antibody
<i>Molecular Weight</i>	~149 kDa

Summary of Key Pharmacokinetic Parameters

<i>Linearity/non-linearity</i>	Exposure increases in a dose-proportional manner within the dose range for efficacy.
<i>Steady state</i>	Achieved after 16 weeks of repeated dosing on an every 3-week regimen.
<i>Plasma half-life</i>	22 days.
<i>C_{max}</i>	Not reported.
<i>C_{min}</i>	22 µg/mL at a dose of 2 mg/kg every 3 weeks. 29 µg/mL at a dose of 200 mg every 3 weeks.
<i>AUC</i>	794 µg-day/mL at a dose of 2 mg/kg every 3 weeks. 1053 µg-day/mL at a dose of 200 mg every 3 weeks.
<i>Bioavailability</i>	Completely bioavailable.
<i>Absorption</i>	Administered IV.
<i>Protein Binding</i>	Does not bind to plasma proteins in a specific manner.
<i>Volume of Distribution</i>	~6 L.
<i>CSF:Plasma ratio</i>	Not determined.
<i>Semen:Plasma ratio</i>	Not determined.
<i>Renal Clearance</i>	Not reported.
<i>Renal Impairment</i>	No dose adjustment required for patients with mild to moderate renal impairment. Coadministration in patients with severe renal impairment has not been studied.
<i>Hepatic Impairment</i>	No dose adjustment required for patients with mild hepatic impairment. Coadministration in patients with moderate-severe hepatic impairment has not been studied.

Metabolism and Distribution

<i>Metabolised by</i>	Catabolised through non-specific pathways.
<i>Inducer of</i>	None reported.
<i>Inhibitor of</i>	None reported.
<i>Transported by</i>	None reported.

Pembrolizumab PK Fact Sheet

Reviewed July 2022

Page 2 of 2

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

References

Unless otherwise stated (see below), information is from:

Keytruda SmPC, Merck Sharp & Dohme Ltd.

Keytruda Prescribing Information, Merck & Co., Inc.